MDMx was found amplified or overexpressed in 10–20% of breast cancers, glioblastomas, retinoblastomas, and soft tissue sarcomas[3,13-15] in the presence of wild-type TP53, which confirmed that aberrant expression of MDMx may contribute to tumor formation by inhibiting TP53 activity. Here, MDM4 is linked to breast cancer.